Clinical Trial

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Name: Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells — clinical trial record (NCT03535246)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2018-05-13; most recent amendment 2026-06-18.

Trial Details

NCT Number	NCT03535246
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Cancer
Enrollment	100 participants
Start Date	2025-07-01
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-22